DM Clinical Research, a Houston-based integrated clinical research network, is commemorating its 20th anniversary, a milestone that underscores its evolution from a vision of accessible, patient-centered research into one of the nation's leading networks. Founded in 2006, the organization has expanded to more than 35 research sites, providing access to a patient population of 1.97 million across 32 therapeutic areas. Over the past two decades, it has enrolled over 35,000 patients in clinical trials, contributing to the development of safe, life-changing therapies globally.
The anniversary, themed "Champions of Clinical Research: 20 Years of Impact," reflects the collective effort of employees, patients, and partners. Founder and CEO Mohammad Millwala emphasized the people at the core of the organization: "When I think about DM Clinical Research, I think first about the people, the employees who have poured their talent and heart into this organization, and the patients who have trusted us to be part of their healthcare journey." He noted that while the company has experienced significant growth, its commitment to patients and meaningful work remains unchanged.
DM Clinical Research partners with pharmaceutical, biotechnology, and contract research organizations to conduct high-quality trials, focusing on strong enrollment, diverse patient access, and operational excellence. Its integrated model combines local physician relationships and patient access with centralized infrastructure, ensuring quality and speed for sponsors. The company has been recognized with industry honors, including the SPRIA Award for vaccine enrollment, the Excellence in Patient Centricity Award, ViE's Best Clinical Trial Network Award, and the SCRS Site Spark Award. In 2025, Millwala received the SCRS Christine K. Pierre Site Impact Award for his leadership.
As the company enters its third decade, it plans continued expansion into underserved communities, broader therapeutic expertise, and investment in innovative technologies to improve patient access. Millwala added, "The next chapter for DM Clinical is about expanding access to research, embracing new technologies, and ensuring more patients have the opportunity to participate in clinical trials that can change lives." This commitment to expanding access is pivotal, as it addresses disparities in clinical trial participation and accelerates the delivery of new therapies to diverse populations.
